Product: Brd4 Mouse Monoclonal Antibody
Catalog: BF9440
Description: Mouse monoclonal antibody to Brd4
Application: WB
Reactivity: Human
Prediction: Mouse, Rat, Pig, Zebrafish, Bovine, Horse, Sheep, Dog, Chicken
Mol.Wt.: 200kDa; 152kD(Calculated).
Uniprot: O60885

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Mouse
Application:
WB 1:500-1:3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Monoclonal [AFfirm9440]
Specificity:
Brd4 Mouse Monoclonal Antibody detects endogenous levels of total Brd4.
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Brd4; BRD4-NUT FUSION; BRD4-NUT fusion oncoprotein; BRD4_HUMAN; Bromodomain containing 4; bromodomain containing protein 4; Bromodomain-containing protein 4; CAP; chromosome associated protein; HUNK1; HUNKI; MCAP; Mitotic chromosome-associated protein; Protein HUNK1;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
O60885 BRD4_HUMAN:

Ubiquitously expressed.

Sequence:
MSAESGPGTRLRNLPVMGDGLETSQMSTTQAQAQPQPANAASTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETEIMIVQAKGRGRGRKETGTAKPGVSTVPNTTQASTPPQTQTPQPNPPPVQATPHPFPAVTPDLIVQTPVMTVVPPQPLQTPPPVPPQPQPPPAPAPQPVQSHPPIIAATPQPVKTKKGVKRKADTTTPTTIDPIHEPPSLPPEPKTTKLGQRRESSRPVKPPKKDVPDSQQHPAPEKSSKVSEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPEEPVVAVSSPAVPPPTKVVAPPSSSDSSSDSSSDSDSSTDDSEEERAQRLAELQEQLKAVHEQLAALSQPQQNKPKKKEKDKKEKKKEKHKRKEEVEENKKSKAKEPPPKKTKKNNSSNSNVSKKEPAPMKSKPPPTYESEEEDKCKPMSYEEKRQLSLDINKLPGEKLGRVVHIIQSREPSLKNSNPDEIEIDFETLKPSTLRELERYVTSCLRKKRKPQAEKVDVIAGSSKMKGFSSSESESSSESSSSDSEDSETEMAPKSKKKGHPGREQKKHHHHHHQQMQQAPAPVPQQPPPPPQQPPPPPPPQQQQQPPPPPPPPSMPQQAAPAMKSSPPPFIATQVPVLEPQLPGSVFDPIGHFTQPILHLPQPELPPHLPQPPEHSTPPHLNQHAVVSPPALHNALPQQPSRPSNRAAALPPKPARPPAVSPALTQTPLLPQPPMAQPPQVLLEDEEPPAPPLTSMQMQLYLQQLQKVQPPTPLLPSVKVQSQPPPPLPPPPHPSVQQQLQQQPPPPPPPQPQPPPQQQHQPPPRPVHLQPMQFSTHIQQPPPPQGQQPPHPPPGQQPPPPQPAKPQQVIQHHHSPRHHKSDPYSTGHLREAPSPLMIHSPQMSQFQSLTHQSPPQQNVQPKKQELRAASVVQPQPLVVVKEEKIHSPIIRSEPFSPSLRPEPPKHPESIKAPVHLPQRPEMKPVDVGRPVIRPPEQNAPPPGAPDKDKQKQEPKTPVAPKKDLKIKNMGSWASLVQKHPTTPSSTAKSSSDSFEQFRRAAREKEEREKALKAQAEHAEKEKERLRQERMRSREDEDALEQARRAHEEARRRQEQQQQQRQEQQQQQQQQAAAVAAAATPQAQSSQPQSMLDQQRELARKREQERRRREAMAATIDMNFQSDLLSIFEENLF

PTMs - O60885 As Substrate

Site PTM Type Enzyme
S5 Phosphorylation
Y65 Phosphorylation
K91 Sumoylation
K91 Ubiquitination
K99 Ubiquitination
T103 Phosphorylation
T109 Phosphorylation
K111 Acetylation
K111 Ubiquitination
K155 Ubiquitination
K177 Methylation
R179 Methylation
R181 Methylation
R183 Methylation
T204 Phosphorylation
T296 Phosphorylation
T299 Phosphorylation
T315 Phosphorylation
T316 Phosphorylation
K317 Acetylation
S324 Phosphorylation
S325 Phosphorylation
K333 Acetylation
S338 Phosphorylation
K346 Acetylation
S351 Phosphorylation
S358 Phosphorylation
K362 Acetylation
K367 Acetylation
K368 Acetylation
K404 Methylation
K404 Ubiquitination
K406 Methylation
R453 Methylation
S469 Phosphorylation
S470 Phosphorylation
S484 Phosphorylation
S488 Phosphorylation
S492 Phosphorylation
S494 Phosphorylation
S498 Phosphorylation
S499 Phosphorylation
T500 Phosphorylation
S503 Phosphorylation
S578 Phosphorylation
S579 Phosphorylation
S581 Phosphorylation
S584 Phosphorylation
T598 Phosphorylation
Y599 Phosphorylation
S601 Phosphorylation
S619 Phosphorylation
K624 Ubiquitination
K629 Ubiquitination
K660 Ubiquitination
S673 Phosphorylation
K685 Acetylation
K694 Sumoylation
K694 Ubiquitination
S705 Phosphorylation
K726 Acetylation
K727 Acetylation
S858 Phosphorylation
T942 Phosphorylation
S1045 Phosphorylation
K1050 Sumoylation
S1051 Phosphorylation
Y1054 Phosphorylation
S1064 Phosphorylation
S1070 Phosphorylation
S1074 Phosphorylation
T1080 Phosphorylation
S1083 Phosphorylation
S1100 Phosphorylation
K1111 Acetylation
K1111 Sumoylation
K1114 Acetylation
S1117 Phosphorylation
S1126 Phosphorylation
T1186 Phosphorylation
K1197 Sumoylation
S1201 Phosphorylation
S1204 Phosphorylation
T1211 Phosphorylation
T1212 Phosphorylation
S1215 O-Glycosylation
K1218 Ubiquitination
S1223 Phosphorylation

PTMs - O60885 As Enzyme

Substrate Site Source
P24928 (POLR2A) S1616 Uniprot

Research Backgrounds

Function:

Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters. Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6. BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II. Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II. According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo. In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B. Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters.

Acts as a chromatin insulator in the DNA damage response pathway. Inhibits DNA damage response signaling by recruiting the condensin-2 complex to acetylated histones, leading to chromatin structure remodeling, insulating the region from DNA damage response by limiting spreading of histone H2AX/H2A.x phosphorylation.

PTMs:

Phosphorylation by CK2 disrupt the intramolecular binding between the bromo domain 2 and the NPS region and promotes binding between the NPS and the BID regions, leading to activate the protein and promote binding to acetylated histones. In absence of phosphorylation, BRD4 does not localize to p53/TP53 target gene promoters, phosphorylation promoting recruitment to p53/TP53 target promoters.

Subcellular Location:

Nucleus. Chromosome.
Note: Associates with acetylated chromatin (PubMed:21890894, PubMed:16109376). Released from chromatin upon deacetylation of histones that can be triggered by different signals such as activation of the JNK pathway or nocodazole treatment (PubMed:21890894, PubMed:16109376). Preferentially localizes to mitotic chromosomes, while it does not localizes to meiotic chromosomes (PubMed:21890894, PubMed:16109376).

Chromosome.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Ubiquitously expressed.

Subunit Structure:

Binds acetylated histone H4. Interacts with p53/TP53; the interaction is direct. Interacts (via CTD region) with CDK9 and CCNT1, acting as an associated component of P-TEFb complex. Interacts with RELA (when acetylated at 'Lys-310'). Interacts (via NET domain) with NSD3, CHD4, BICRA and ATAD5. The interaction with BICRA bridges BRD4 to the GBAF complex. Interacts (via NET domain) with JMJD6 (via JmjC and N-terminal domains); the interaction is stronger in presence of ssRNA and recruits JMJD6 on distal enhancers. Interacts with NSD3. Isoform B: interacts with NCAPD3 and SMC2.

(Microbial infection) Interacts with bovine papillomavirus type 1 regulatory protein E2. This interactions may serve for the tethering of viral genomes to host mitotic chromosomes allowing successful partitioning of the viral genome during cell division.

(Microbial infection) Interacts with Epstein-Barr virus (EBV) protein EBNA1; this interaction facilitates transcriptional activation by EBNA1.

(Microbial infection) Interacts with human herpes virus-8 (HHV-8) protein LANA.

Family&Domains:

The NET domain mediates interaction with a number of chromatin proteins involved in transcription regulation (NSD3, JMJD6, CHD4, GLTSCR1 and ATAD5).

The C-terminal (CTD) region mediates interaction and recruitment of CDK9 and CCNT1 subunits of the P-TEFb complex (PubMed:16109376, PubMed:16109377). It is also required for maintenance of higher-order chromatin structure (PubMed:22334664).

The 2 bromo domains mediate specific binding to acetylated histones via Asn-140 and Asn-433, respectively (PubMed:20871596). The exact combination of modified histone tails required to recruit BRD4 to target genes is still unclear. The first bromo domain has high affinity for acetylated histone H4 tail, whereas the second bromo domain recognizes multiply acetylated marks in histone H3 (PubMed:22464331). A number of specific inhibitors bind competitively to acetyl-lysine-binding residues Asn-140 and Asn-433, promoting removal from acetylated histones. Many of these inhibitors are benzodiazepine derivatives (PubMed:22137933, PubMed:22136404, PubMed:23517011, PubMed:23530754).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.